The Food and Drug Administration this week is weighing what would be a first-ever approval of a daily birth-control pill for use without a prescription — a step that could allow many more people to access the most commonly used reversible contraception method in the U.S., policy experts say.
FDA advisory committees meeting jointly Tuesday and Wednesday will review an application submitted by drugmaker Perrigo PRGO to switch from prescription to over-the-counter availability for Opill, a daily contraceptive first approved…
This article was originally published by Marketwatch.com. Read the original article here.
